



PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/801,286		
		Filing Date	03/16/2004		
		First Named Inventor	Joachim MIERAU		
		Art Unit	1614		
		Examiner Name	SPIVACK		
Sheet	1	of	3	Attorney Docket Number	1/1472

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
PS		US- 2001/0016582 A1	08/23/2001	Cincotta, A. H.	
PS		US- 4,855,306	08/08/1989	Markstein, R. et al	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
PS		WO 02/069974 A1	09/12/2002	Holman, A.		
PS		WO 02/060423 A2	08/08/2002	Otsuka Pharm. Co.		
PS		WO 01/41763 A1	06/14/2001	U. of Cincinnati		
PS		WO 90/13294 A1	11/15/1990	Whitby Res. Inc.		
PS		EP 1 099 441 A2	05/16/2001	Pfizer Prod., Inc.		

Examiner Signature	<i>Phillip Spivack</i>	Date Considered	8/4/06
--------------------	------------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

1/1472

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/801,286
				Filing Date	03/16/2004
				First Named Inventor	Joachim MIERAU
				Art Unit	1614
				Examiner Name	Spivack
Sheet	3	of	3	Attorney Docket Number	1/1472

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
PS		FERNANDEZ-LOPEZ, J. A. ET AL; "Pharmacological Approaches for the Treatment of Obesity"; Drugs, Aids International Ltd. AT; 2002, 62 (6); pgs. 915-944.		
PS		WILLNER, P. ET AL; "Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole"; Psychopharmacology, Germany; 1994, 115 (4), pgs. 454-462.		
PS		NAGASHIMA, M. ET AL; "Hyperthermia Induced by the Dopamine D1 Receptor Agonist SKF38393 in Combination With the Dopamine D2 Receptor Agonist Talipexole in the Rat"; Pharmacology Biochemistry and Behavior; 1992, Vol. 43, pgs. 993-997.		
PS		DOMINO, E. F. ET AL; "Talipexole or pramipexole combinations with chloro-APB (SKF 82958) in MPTO-induced hemiparkinsonian monkeys"; European J of Pharmacology; 1997, 325; pgs 137-144.		
PS		TERRY, P. ET AL; "Dopamine Receptor Subtype Agonists and Feeding Behavior"; Obesity Research; 1995, Vol. 3, Supp. 4; pgs 515S-523S.		

Examiner Signature	Phyllis Spivack	Date Considered	8/4/06
--------------------	-----------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.